OncoMatch/Clinical Trials/NCT07313241
Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy (RANGER)
Is NCT07313241 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Androgen Deprivation Therapy (ADT) for prostate cancer.
Treatment: Androgen Deprivation Therapy (ADT) — This Phase II, single arm study evaluates a PSA-response-adapted approach to salvage radiotherapy after radical prostatectomy for prostate cancer. All participants will receive hypo-fractionated stereotactic radiotherapy to the prostate fossa. At 5 weeks, biochemical response will be assessed. responders will proceed to observation, while non responders will receive sequential pelvic nodal radiotherapy and 4 months of androgen deprivation therapy (ADT). The study aims to determine whether this response base approach achieves non inferior 2 year freedom from progression compared with historical outcomes using routine pelvic nodal radiotherapy and ADT in all patients.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: prostatectomy — localized
treated with prostatectomy in the localized setting within 10 years
Cannot have received: androgen deprivation therapy
Exception: ≤ 3 months allowed with ≥30 day washout and testosterone >50ng/mL
Prior androgen deprivation therapy (ADT) > 3 months... For shorter courses of either, at least 30 day 'wash out' period is required with confirmation of resolved castration of testosterone to >50ng/mL.
Cannot have received: anti-androgen therapy
Exception: ≤ 30 days allowed with ≥30 day washout and testosterone >50ng/mL
anti-androgen therapy (AAT) of > 30 days. For shorter courses of either, at least 30 day 'wash out' period is required with confirmation of resolved castration of testosterone to >50ng/mL.
Cannot have received: testosterone replacement therapy
Exception: must be stopped with demonstration of detectable PSA ≥0.05ng/mL and non-castrate testosterone >50ng/mL after 14 days of TRT cessation
Ongoing testosterone replacement therapy (TRT) with refusal to discontinue (must be stopped with demonstration of detectable PSA ≥0.05ng/mL and non-castrate testosterone >50ng/mL after 14 days of TRT cessation)
Cannot have received: pelvic radiotherapy
Prior pelvic radiotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UT Southwestern Medical Center-Dallas · Dallas, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07313241 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior androgen deprivation therapy, anti-androgen therapy, testosterone replacement therapy disqualifies patients from enrollment.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages